Details of the Drug

General Information of Drug (ID: DM1WNGJ)

Drug Name
DFP-10917
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Acute lymphoblastic leukaemia 2A85 Phase 1/2 [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 252.23
Logarithm of the Partition Coefficient (xlogp) -2.4
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
Chemical Identifiers
Formula
C10H12N4O4
IUPAC Name
(2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolane-3-carbonitrile
Canonical SMILES
C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)C#N
InChI
InChI=1S/C10H12N4O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-2,5-6,8-9,15-16H,4H2,(H2,12,13,17)/t5-,6+,8-,9+/m0/s1
InChIKey
DCYBPMFXJCWXNB-JWIUVKOKSA-N
Cross-matching ID
PubChem CID
119184
ChEBI ID
CHEBI:145435
CAS Number
135598-68-4
DrugBank ID
DB11667
TTD ID
D0KE1F
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA replication (DNA repli) TTABD5E NOUNIPROTAC Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03926624) Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT00824161) Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT01702155) Phase I/II Study of DFP-10917 in Patients With Acute Leukemia. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)